A Phase 2/3 interventional study of Evolocumab and Placebo in Homozygous Familial Hypercholesterolemia, sponsored by Amgen. Completed at 21 sites in 12 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-11-29.
Sponsored by Amgen · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to determine the safety, tolerability, and efficacy of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia (HoFH).
Study Masking:
Part A: Open Label Part B: Double Blind
68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.
This study's enrollment of 58 is above the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.
Browse Homozygous Familial Hypercholesterolemia studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received open-label evolocumab 420 mg subcutaneously once a month for 12 weeks.
Biological: Evolocumab
Participants received double-blind evolocumab 420 mg subcutaneously once a month for 12 weeks.
Biological: Evolocumab
Participants received double-blind placebo subcutaneously once a month for 12 weeks.
Drug: Placebo
Administered by subcutaneous injection
Also known as: AMG 145, Repatha
Administered by subcutaneous injection
Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
LDL-C was quantified using the ultracentrifugation method.
Time frame: Baseline and Week 12
Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
LDL-C was quantified using the ultracentrifugation method.
Time frame: Baseline and Week 12
Part A: Change From Baseline in LDL-C at Week 12
LDL-C was quantified using the ultracentrifugation method.
Time frame: Baseline and Week 12
Part A: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
Time frame: Baseline and Week 12
Part A: Percent Change From Baseline in Apolipoprotein B at Week 12
Time frame: Baseline and Week 12
Part A: Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12
Time frame: Baseline and Week 12
Part A: Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
Time frame: Baseline and Week 12
Part A: Percentage of Participants With 15% or Greater Reduction in LDL-C From Baseline at Week 12
LDL-C was quantified using the ultracentrifugation method.
Time frame: Baseline and Week 12
Part A: Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) at Week 12
Time frame: Baseline and Week 12
Part B: Percent Change From Baseline in LDL-C at the Mean of Weeks 6 and 12
LDL-C was quantified using the ultracentrifugation method.
Time frame: Baseline and Weeks 6 and 12
Part B: Percent Change From Baseline in Apolipoprotein B at Week 12
Time frame: Baseline and Week 12
Part B: Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 6 and 12
Time frame: Baseline and Weeks 6 and 12
Part B: Percent Change From Baseline in Lipoprotein (a) at Week 12
Time frame: Baseline and Week 12
Part B: Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 6 and 12
Time frame: Baseline and Weeks 6 and 12
Male and female adults and adolescents ages ≥ 12 to ≤ 65 years (≥ 12 to ≤ 80 years in Part B) with a diagnosis of homozygous familial hypercholesterolemia (HoFH) were eligible for this study. The first participant enrolled on 05 April 2012 and the last participant enrolled on 08 November 2013.
| Milestone | Part A: Evolocumab | Part B: Placebo | Part B: Evolocumab |
|---|---|---|---|
| Started | 8 | 17 | 33 |
| Received treatment | 8 | 16 | 33 |
| Completed | 8 | 16 | 33 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
LDL-C was quantified using the ultracentrifugation method.
| percent change | Part A: Evolocumab |
|---|---|
| Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 | -16.5 ± 6.7 |
LDL-C was quantified using the ultracentrifugation method.
| mg/dL | Part A: Evolocumab |
|---|---|
| Part A: Change From Baseline in LDL-C at Week 12 | -70.6 ± 32.3 |
| percent change | Part A: Evolocumab |
|---|---|
| Part A: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12 | -16.6 ± 6.5 |
| percent change | Part A: Evolocumab |
|---|---|
| Part A: Percent Change From Baseline in Apolipoprotein B at Week 12 | -14.9 ± 5.0 |
| percent change | Part A: Evolocumab |
|---|---|
| Part A: Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12 | -18.319 ± 6.058 |
| percent change | Part A: Evolocumab |
|---|---|
| Part A: Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12 | -15.65 ± 4.690 |
LDL-C was quantified using the ultracentrifugation method.
| percentage of participants | Part A: Evolocumab |
|---|---|
| Part A: Percentage of Participants With 15% or Greater Reduction in LDL-C From Baseline at Week 12 | 50.0 |
| ng/mL | Part A: Evolocumab |
|---|---|
| Part A: Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) at Week 12 | -151.3 ± 81.7 |
LDL-C was quantified using the ultracentrifugation method.
| percent change | Part B: Placebo | Part B: Evolocumab |
|---|---|---|
| Part B: Percent Change From Baseline in LDL-C at the Mean of Weeks 6 and 12 | 4.22 ± 4.56 | -25.56 ± 3.28 |
| percent change | Part B: Placebo | Part B: Evolocumab |
|---|---|---|
| Part B: Percent Change From Baseline in Apolipoprotein B at Week 12 | 3.97 ± 4.74 | -19.17 ± 3.46 |
| percent change | Part B: Placebo | Part B: Evolocumab |
|---|---|---|
| Part B: Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 6 and 12 | 2.65 ± 4.42 | -20.24 ± 3.18 |
| percent change | Part B: Placebo | Part B: Evolocumab |
|---|---|---|
| Part B: Percent Change From Baseline in Lipoprotein (a) at Week 12 | 2.43 ± 5.49 | -9.40 ± 4.07 |
| percent change | Part B: Placebo | Part B: Evolocumab |
|---|---|---|
| Part B: Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 6 and 12 | -1.43 ± 4.78 | -12.71 ± 3.53 |
LDL-C was quantified using the ultracentrifugation method.
| percent change | Part B: Placebo | Part B: Evolocumab |
|---|---|---|
| Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 | 7.88 ± 5.26 | -23.05 ± 3.78 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: OL Evolocumab | — | 0/8 (0%) | 4/8 (50%) |
| Part B: DB Placebo | — | 0/16 (0%) | 10/16 (62.5%) |
| Part B: DB Evolocumab | — | 0/33 (0%) | 11/33 (33.3%) |
| Event | Part A: OL Evolocumab | Part B: DB Placebo | Part B: DB Evolocumab |
|---|---|---|---|
| DyspepsiaGastrointestinal disorders | 1/8 | 0/16 | 0/33 |
| NauseaGastrointestinal disorders | 0/8 | 2/16 | 0/33 |
| PainGeneral disorders | 1/8 | 0/16 | 0/33 |
| BronchitisInfections and infestations | 1/8 | 0/16 | 0/33 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 1/8 | 0/16 | 0/33 |
| InfluenzaInfections and infestations | 0/8 | 0/16 | 3/33 |
| Upper respiratory tract infectionInfections and infestations | 0/8 | 1/16 | 3/33 |
| PalpitationsCardiac disorders | 0/8 | 1/16 | 0/33 |
| Abdominal painGastrointestinal disorders | 0/8 | 1/16 | 1/33 |
| Abdominal pain upperGastrointestinal disorders | 0/8 | 1/16 | 0/33 |
| Age, Continuous(years) | Part A: Evolocumab | Part B: Placebo | Part B: Evolocumab | Total |
|---|---|---|---|---|
| Mean | 34.3 ± 12.4 | 32.8 ± 13.7 | 30.3 ± 12.4 | 31.6 ± 12.7 |
| Sex: Female, Male(Participants) | Part A: Evolocumab | Part B: Placebo | Part B: Evolocumab | Total |
|---|---|---|---|---|
| Female | 2 | 8 | 16 | 26 |
| Male | 6 | 9 | 17 | 32 |
| Race/Ethnicity, Customized(participants) | Part A: Evolocumab | Part B: Placebo | Part B: Evolocumab | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 | 2 |
| Black or African American | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| White | 8 | 16 | 29 | 53 |
| Other | 0 | 0 | 3 | 3 |
| Race/Ethnicity, Customized(participants) | Part A: Evolocumab | Part B: Placebo | Part B: Evolocumab | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 8 | 17 | 32 | 57 |
| Stratification Factor: Low-Density Lipoprotein Cholesterol (LDL-C) Level(participants) | Part A: Evolocumab | Part B: Placebo | Part B: Evolocumab | Total |
|---|---|---|---|---|
| < 420 mg/dL | 0 | 11 | 21 | 32 |
| ≥ 420 mg/dL | 0 | 6 | 12 | 18 |
| Missing | 8 | 0 | 0 | 8 |
| LDL-C Concentration(mg/dL) | Part A: Evolocumab | Part B: Placebo | Part B: Evolocumab | Total |
|---|---|---|---|---|
| Part A | 441.7 ± 113.3 | NA ± NA | NA ± NA | 441.7 ± 113.3 |
| Part B | NA ± NA | 335.8 ± 146.0 | 356.0 ± 134.5 | 349.4 ± 137.2 |
| Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL) | Part A: Evolocumab | Part B: Placebo | Part B: Evolocumab | Total |
|---|---|---|---|---|
| Part A | 470.6 ± 117.8 | NA ± NA | NA ± NA | 470.6 ± 117.8 |
| Part B | NA ± NA | 358.9 ± 149.1 | 374.9 ± 136.9 | 369.7 ± 139.6 |
| Apolipoprotein B Concentration(mg/dL) | Part A: Evolocumab | Part B: Placebo | Part B: Evolocumab | Total |
|---|---|---|---|---|
| Part A | 269.1 ± 53.0 | NA ± NA | NA ± NA | 269.1 ± 53.0 |
| Part B | NA ± NA | 208.6 ± 79.5 | 208.3 ± 68.4 | 208.4 ± 71.4 |
4 further baseline measures are reported on the registry.
Ran from Apr 2012 to primary completion in Jan 2014, 21 months.
Results were first posted in Oct 2015, 1 year 8 months after primary completion. A results delay was requested in May 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab
Homozygous Familial Hypercholesterolemia →